Standard Biotools (LAB) Short term Debt (2010 - 2024)

Standard Biotools (LAB) has 6 years of Short term Debt data on file, last reported at $54.8 million in Q2 2024.

• On a quarterly basis, Short term Debt rose 1095.35% year-over-year to $54.8 million in Q2 2024; TTM through Jun 2024 was $54.8 million, a 1095.35% increase from a year earlier, with the FY2023 full-year figure at $5.0 million, up 140.04% from the prior year.
• Short term Debt for Q2 2024 stood at $54.8 million, up from $5.0 million in the prior quarter.
• Over the last five years, Short term Debt for LAB reached as high as $54.8 million in Q2 2024 and fell as low as $833000.0 in Q3 2022.
• Historically, Short term Debt has averaged $10.8 million across 3 years, with a median of $4.6 million in 2023.
• Across the five-year window, Short term Debt jumped 140.04% in 2023 and soared 1095.35% in 2024, its largest moves.
• Year by year, Short term Debt stood at $2.1 million in 2022, then jumped by 140.04% to $5.0 million in 2023, then jumped by 995.66% to $54.8 million in 2024.
• Per Business Quant data, the three most recent Short term Debt figures were $54.8 million in Q2 2024, $5.0 million in Q4 2023, and $5.0 million in Q3 2023.